Back to School: How biopharma can reboot drug development. Access exclusive analysis here

HopeMed: Targeting PRLR for chronic diseases

How HopeMed’s anti-PRLR antibody could treat endometriosis, alopecia with fewer side effects

HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia.

Hope Medicine Inc. has exclusive worldwide rights from Bayer AG to develop and commercialize the mAb, BAY 1158061, for endometriosis, male and female pattern hair loss and other chronic diseases with dysregulated PRL signaling.

Although the underlying causes of endometriosis are not clear, high

Read the full 748 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers